Research programme: Pim kinase inhibitors - Array BioPharmaAlternative Names: AR 29; ARRY-Pim-i
Latest Information Update: 12 Aug 2011
At a glance
- Originator Array BioPharma
- Class Small molecules
- Mechanism of Action Protein-serine-threonine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Myeloid leukaemia